DRIO News

Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management

Dario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms

Dario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members

Dario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio

DarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date

DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year

DarioHealth Presents New Data Demonstrating Significant Reduction in Medical Costs Among Employer Populations Using Its Digital Health Platform

DarioHealth to Report Third Quarter 2025 Results on Thursday, November 13, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of DarioHealth Corp. (NASDAQ: DRIO)